31results about How to "Promote cell death" patented technology

The present invention relates to a method for preparing a peptide having a stable, internally constrained alpha-helical, beta-sheet/beta-turn, 3₁₀-helical, or pi-helical region and a method of stabilizing an alpha-helical, beta-sheet/beta-turn, 3₁₀-helical, or pi-helical region within a peptide structure. The resulting peptides and methods of using them are also disclosed.

A medical illumination device including a base, a light housing and a flexible body. The base includes a power source and an attachment component. The attachment component further includes a first portion and a second portion, the first portion attachable to an attachment point and the second portion repositionable relative to the first portion without detaching the first portion from the attachment point. The flexible body has a self-sustaining shape with at least one bendable shaft positioned inside the flexible body. The base provides stability for repositioning of the flexible body. The base has sufficient surface area contacting the attachment point, sufficient base weight, and sufficient holding strength to effectively provide stability for repositioning of the flexible body. The base comprises at least 50% of the weight of the device and has a surface area of at least 1.0 square inch.

A medical illumination device including a sterile package, a base, a light housing, and a flexible body. An attachment component of the base may include an adhesive exposable upon removal of the component from the package. The base may have sufficient surface area, sufficient base weight, and sufficient holding strength to effectively provide stability for repositioning. The base may be 50% of the device weight and have a surface area of 1.0 square inch. A second portion of the attachment component may be repositionable without detaching the first portion. Portions may be separately removable from the sterile package. The device may include a second flexible body attaching a second light source to the base. The device may provide a base containing a power means, a lighting means, and a flexible body means. The device may also include a sterile packaging means and repositioning means.

The present invention relates to compositions and methods for making and using Omi-related and IAP-cleaving nucleotide sequences, mutant nucleotide sequences, and polypeptide sequences expressed therefrom, including both biologically active and inactive molecules. The present invention relates to cleaving IAP using an Omi polypeptide.

Methods for regulating cancer cell growth and survival, inhibiting cancer cell growth, promoting cancer cell death, and/or treating a cancer make use of antagonists of a type I BMP receptor. In some embodiments the cancer is a lung cancer and the cancer cell is a lung cancer cell.

The present invention relates generally to compositions useful in therapies involving the selective destruction of tumor cells in vivo. In particular, this invention relates to a conjugate which comprises a target recognition segment and an active cytotoxic segment. The target recognition segment comprises a receptor specific to NK cells, wherein the receptor binds to a cellular ligand expressed on the surface of a tumor cell, and the active segment comprises an agent capable of exerting a cytotoxic effect on the tumor cell. The target recognition segment derived form the natural killer receptor NKp3O has been found to be particularly effective in vivo.

It is proposed that cancer cells express SATB1, and that SATB1 acts as a determinant for the acquisition of metastatic activity by controlling expression of a specific set of genes that promote metastatic activity. In order for cancer cells to gain the ability to metastasize, SATB1 re-organizes or re-packages genomic sequences in a specific manner to allow a switch in the pattern of gene expression. SATB1 expression was found restricted mainly to aggressive cancer cells where it may regulate the genetic and epigenetic changes that program the steps involved in the metastatic process. The present invention describes reagents and tools to detect the SATB1 protein for use in diagnosis and prognosis of aggressive cancers and therapeutics to inhibit SATB1 protein to deplete its expression in metastatic and aggressive cancers.

The use of eriocalyxin B in the manufacture of medicaments for treating leukemia, wherein the leukemia include leukemia containing AML1-ETO fusion protein, acute promyelocytic leukemia, acute myelocytic leukemia and lymphocytic leukemia. Eriocalyxin B increases the level of peroxidate and influences the phosphorylation and degradation of IκBα to prevent NF-κB from getting into the nucleus in order to inhibition NF-κB pathway. Eriocalyxin B can decrease the phosphorylation of ERI1/2 and inhibit MAPK pathway. Eriocalyxin B can extend the life span of mice and decrease tumor volume in mice model of C57 leukemia and tumor transplantation.

Protein logic gates are made from autoregulated fusion proteins comprising an output domain and a plurality of input domains, wherein at least one of the input domains is heterologous to the output domain, and the input domains interact with each other to allosterically and external, ligand-dependently regulate the output domain. The output domain may be constitutively active, and in the absence of the ligand, the input domains interact to inhibit the output domain. The activity of the output domain is user discretionary, and may include activities that are catalytic, label-generative, metabolic-regulative, apototic, specific-binding, etc. Multiple input domains can cooperatively regulate the fusion protein in a wide variety of functionalities, including as an OR-gate, an AND-gate, and an AND-NOT-gate. The gates may be incorporated into cells and therein used to modulate cell function.

Isolated extracts of Rhodiola crenulata and their constituents sensitize tumor cells to cancer therapies, such as tamoxifen, retinoids, and radiation, and act to potentiate radiation therapy in the treatment of cancer, with or without adjuvant chemotherapy. Methods are provided for inhibiting the P13kinase/AKT pathway in cancer cells, a general survival pathway which leads to resistance of many tumors to typical therapies; decreasing cyclooxygenase (COX) activities in cancer cells, another pathway known to increase resistance to tumors; inhibiting telomerase activity in cancer cells, an activity notable for its ability to increase the life span of the cells; enhancing the ATM (Ataxia-Telangiectasia Mutated) response in cells, which is involved in DNA damage sensing and repair; modulating cellular response to oxidation, which effects the other signaling pathways on numerous levels; and altering usage of metabolic energy pathways.

A method for treating an cancer disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker.

The present invention relates to the use of an inhibitor of Rad18 expression or activity, in treating a tumor or in sensitizing a patient affected with a tumor, to a treatment with an antineoplastic agent that is a DNA damaging chemotherapeutic agent so to both reduce the self renewal of cancer stem cells and increase the DNA damage response thus boosting apoptotic cell death.

The present invention provides a phenothiazine derivative or a pharmaceutically acceptable salt thereof, a method of preparing a compound selected therefrom and a pharmaceutical composition containing the compound as an active ingredient. The phenothiazine derivative according to the present invention has an effect of inhibiting calmodulin (CaM; calcium-modulated protein) and thus helps cell death by maintaining the intracellular level of calcium in lung cancer cells at high concentration. Accordingly, the phenothiazine derivative according to the present invention can be usefully used to prevent or treat malignant tumors such as lung cancer.

Novel substituted imidazopyridine and oxazolopyridine compounds that are useful as inhibitors of HIF-2α and inducers of ferroptosis through perturbations in iron metabolism, synthetic methods for making said compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions to treat disorders associated with dysfunction of HIF-2α or iron metabolism.

This invention demonstrates that the PEG10 protein suppresses apoptosis and promotes cancer cell growth. Furthermore, PEG10 protein was found to be degraded through interaction with SIAH1 protein. This invention provides methods of regulating cell growth and cell death using the PEG10 protein. Furthermore, the present invention provides methods of screening for novel anticancer agents which use the PEG10 protein. The screening of this invention enables development of pharmaceutical agents that induce apoptosis and suppress cell growth by specifically targeting cancer cells. In particular, since the PEG10 protein is specifically expressed in hepatoma cells, it is an ideal target molecule for diagnosis and treatment of hepatoma.